Search

Heron Therapeutics Inc

Gesloten

SectorGezondheidszorg

0.48 -2.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.47

Max

0.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.2M

-8.1M

Verkoop

-5.9M

35M

EPS

-0.04

Winstmarge

-23.367

Werknemers

128

EBITDA

-6.8M

-7.6M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+300% upside

Dividenden

By Acuity

Volgende Winsten

10 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-133M

97M

Vorige openingsprijs

2.52

Vorige sluitingsprijs

0.48

Heron Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

7 aug 2026, 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

7 aug 2026, 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

7 aug 2026, 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

7 aug 2026, 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

7 aug 2026, 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

7 aug 2026, 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

7 aug 2026, 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

7 aug 2026, 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

7 aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

7 aug 2026, 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

7 aug 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

7 aug 2026, 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

7 aug 2026, 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

7 aug 2026, 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

7 aug 2026, 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

7 aug 2026, 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

7 aug 2026, 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

7 aug 2026, 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

7 aug 2026, 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

7 aug 2026, 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

7 aug 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

7 aug 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

7 aug 2026, 23:16 UTC

News

Hawaiian Electric Industries reported Q2 revenues of $939.70 million, but adjusted EPS of $0.13 missed estimates by $0.06. Shares are trading roughly flat in after-hours.

7 aug 2026, 23:16 UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

7 aug 2026, 23:11 UTC

News

Ashland Inc. is exploring a potential sale amid takeover interest, while announcing a quarterly cash dividend of $0.42 per share. Shares lower in after-market trading.

7 aug 2026, 23:06 UTC

News

Baker Hughes reported a stable U.S. rig count of 588, with oil rigs rising to 454 and gas rigs declining to 124. Shares were little changed in after-market trading.

7 aug 2026, 23:06 UTC

News

Kimberly-Clark Corp shares are lower in after-market trading, reflecting ongoing challenges with revenue and margins amid rising input costs and competition.

7 aug 2026, 23:06 UTC

News

Photronics Inc shares are lower in after-market trading following a class action lawsuit alleging misleading statements about its product pipeline and demand stability.

7 aug 2026, 23:06 UTC

News

Morgan Stanley shares are lower after-market, reflecting a slight decline. The movement follows the bank's $400 million Bitcoin purchases amid uncertain market conditions.

Peer Vergelijking

Prijswijziging

Heron Therapeutics Inc Prognose

Koersdoel

By TipRanks

300% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD  300%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Heron Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat